Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
OLIG2-Expressing Progenitors May Initiate Medulloblastoma Tumor Formation.
|
31492681 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that TFAP2B, ALK and a novel marker OLIG2 may serve as surrogate markers for PAX3/7-FOXO1 status what is especially beneficial in cases where poor quality tumour tissue is not suitable for reliable genetic analyses or shows inconclusive result.
|
31493794 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides histone H3K27M mutation, immunohistochemical staining also showed that the tumor cells were positive for oligodendrocyte lineage transcription factor 2 and ATRX.
|
28880421 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the combined FoxG1/Olig-2 profile may discriminate H3F3A K27- and G34-mutant tumours and define a prognostically favourable subset in IDH-mutant gliomas, our data show that labelling indices of these transcription factors overlap with adult IDH-mutant and wild-type tumour classes.
|
29053887 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical comparative analysis of GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value.
|
29258767 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We validated this MMS on human glioblastoma tissue sections with the use of immunohistochemistry on preclassified (YKL-40 high or mesenchymal glioblastoma and OLIG2 high or proneural glioblastoma) tumor samples (<i>n</i> = 30).
|
28744448 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this perspective, we will review the role of OLIG2 in tumor initiation, proliferation and phenotypic plasticity in animal models of gliomas and human GSC cell lines, and discuss the underlying mechanisms in the control of tumor growth and potential therapeutic strategies to target OLIG2 in malignant gliomas.
|
28806136 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The tumor was positive for OLIG2 and GFAP and negative for BRAF V600E and IDH1 R132H mutant protein immunostains.
|
29141672 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical (IHC) analysis showed diffuse expression of GFAP, OLIG2 and SOX2 consistent with a tumor of glial lineage.
|
26817999 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Olig2 deletion causes a tumor phenotypic shift from an oligodendrocyte precursor-correlated proneural toward an astroglia-associated gene expression pattern, manifest in downregulation of platelet-derived growth factor receptor-α and reciprocal upregulation of epidermal growth factor receptor (EGFR).
|
27165742 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Induction of the miR-302/367 cluster in extensively mutated U87MG glioblastoma cells drastically suppressed the expression of transformation related proteins, for example, the reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC, and the transcription factors POU3F2, SALL2 and OLIG2, required for the maintenance of glioblastoma stem-like tumor propagating cells.
|
25991553 |
2015 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Two genes studied in detail, MAL and OLIG2, were silenced during transformation, initially through enrichment for H3K27me3 and H3K9me2, commonly methylated in lung cancer, and exert tumor suppressor effects in vivo through modulating cancer-related pathways.
|
24469050 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High expression of proneural gene OLIG2 without EGFRvIII expression may be associated with a favorable clinical outcome; however, IDH1/2 gene status and the extent of LOH regions may indicate that this small subgroup of GBM is a distinct genetic subgroup from oligodendroglial tumors.
|
22736234 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
|
21193945 |
2011 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
1p19q whole loss was also significantly associated with Olig2 overexpression, but was never observed in tumors overexpressing p53 protein.
|
20081802 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We identified a novel mechanism for L1CAM regulation of cell survival as L1CAM knockdown decreased expression of the basic helix-loop-helix transcription factor Olig2 and up-regulated the p21(WAF1/CIP1) tumor suppressor in CD133(+) glioma cells.
|
18676824 |
2008 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Widespread OLIG2 expression discriminates oligodendroglial neoplasms or DNTs from other clear cell primary brain tumour types.
|
17257132 |
2007 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Olig1 and Olig2 were expressed in 26/30 (87%) and 28/30 (93%) of oligodendroglial tumors respectively but in only 9% of glioblastomas (1/11).
|
15164981 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis of 180 primary, metastatic, and non-neural human tumors shows OLIG2 is highly expressed in all diffuse gliomas.
|
15198128 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We investigated the expression of OLIG2 by in-situ hybridisation in 21 brain tumours: nine grade II and III oligodendrogliomas, three grade II oligoastrocytomas, and nine non-oligodendroglial tumours (four grade IV astrocytomas, two meningiomas, a dysembryoplastic neuroepithelial tumour, and two metastases).
|
11498220 |
2001 |